Loading…
MOVICOL READY TO TAKE is a brand name for Sodium. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the treatment of constipation in adults and adolescents (12 years and above). Movicol Ready to Take is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon.
Verbatim from this product's MHRA label. Tap a section to expand.
Movicol Ready to Take should be used directly from the sachet. This product does not need to be diluted with water. Chronic Constipation A course of treatment for constipation with Movicol Ready to Take does not normally exceed 2 weeks, although this can be repeated if required.
As for all laxatives, prolonged use is not usually recommended. Extended use may be necessary in the care of patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson’s disease, or induced by regular constipating medication in particular opioids and antimuscarinics.
Adults, adolescents and older people: 1-3 sachets daily in divided doses, according to individual response. For extended use, the dose can be adjusted down to 1 or 2 sachets daily.
Children (below 12 years old):
Not recommended. Alternative Movicol products are available for children.
Patients with renal insufficiency:
No dosage change is necessary for the treatment of constipation. 0 litre of fluid per day. A course of treatment for faecal impaction with Movicol Ready to Take does not normally exceed 3 days. Adults, adolescents and older people: 8 sachets daily, all of which should be consumed within a 6 hour period.
Children (below 12 years old):
Not recommended. Alternative Movicol products are available for children.
Patients with impaired cardiovascular function:
For the treatment of faecal impaction the dose should be divided so that no more than two sachets are taken in any one hour.
Patients with renal insufficiency:
No dosage change is necessary for treatment of faecal impaction. 5 litres daily) to maintain good health.
8. g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Movicol Ready to Take should be stopped immediately and electrolytes measured and any abnormality should be treated appropriately. 5). 3% of the WHO recommended maximum daily intake for sodium.
When used long term for constipation, the maximum daily dose of this product is equivalent to 28% of the WHO recommended maximum daily intake for sodium. Movicol Ready to Take is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
This medicinal product contains between 159 mg and 162 mg of propylene glycol per sachet. 5. 5 Interaction with other medicinal products and other forms of interaction Macrogol raises the solubility of medicinal products that are soluble in alcohol and relatively insoluble in water.
4). g. anti-epileptics. Therefore, other medicines should not be taken orally for one hour before, during and for one hour after taking Movicol Ready to Take. Movicol Ready to Take may result in a potential interactive effect if used with starch- based food thickeners.
The Macrogol ingredient counteracts the thickening effect of starch, effectively liquefying preparations that need to remain thick for people with swallowing problems. 6 Fertility, Pregnancy and lactation Pregnancy There are limited amount of data from the use of Movicol in pregnant women.
3). Clinically, no effects during pregnancy are anticipated, since systemic exposure to macrogol 3350 is negligible. Movicol Ready to Take can be used during pregnancy. Breastfeeding No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Macrogol 3350 is negligible.
Movicol Ready to Take can be used during breast-feeding. Fertility There are no data on the effects of Movicol on fertility in humans. 3). 7 Effects on ability to drive and use machines Movicol Ready to Take has no influence on the ability to drive and use machines.
The fluid content of Movicol Ready to Take does not replace regular fluid intake and adequate fluid intake must be maintained. Diagnosis of impaction/faecal loading of the rectum should be confirmed by physical or radiological examination of the abdomen and rectum.
8. g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Movicol Ready to Take should be stopped immediately and electrolytes measured and any abnormality should be treated appropriately. 5). 3% of the WHO recommended maximum daily intake for sodium.
When used long term for constipation, the maximum daily dose of this product is equivalent to 28% of the WHO recommended maximum daily intake for sodium. Movicol Ready to Take is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
This medicinal product contains between 159 mg and 162 mg of propylene glycol per sachet. 5.
Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory conditions of the intestinal tract, such as Crohn’s disease and ulcerative colitis and toxic megacolon. 1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Sodium in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
8 Undesirable effects Reactions related to the gastrointestinal tract occur most commonly. These reactions may occur as a consequence of expansion of the contents of the gastrointestinal tract, and an increase in motility due to the pharmacologic effects of Movicol Ready to Take.
Mild diarrhoea usually responds to dose reduction. The frequency of the adverse events for Movicol Ready to Take is not known as it cannot be estimated from the available data. The list of adverse events is based on the current Movicol range of products.
System Organ Class Adverse Event Immune system disorders Allergic reactions, including anaphylactic reactions, dyspnoea and skin reactions (see below). Skin and subcutaneous tissue disorders Allergic skin reactions including angioedema, urticaria, pruritus, rash, erythema.
Metabolism and nutrition disorders Electrolyte disturbances, particularly hyperkalaemia and hypokalaemia. Nervous system disorders Headache. Gastrointestinal disorders Abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, abdominal distension, borborygmi, flatulence, anorectal discomfort.
General disorders and administration site conditions Peripheral oedema. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.